Immuneering Corporation
PublicImmuneering Corporation is now publicly traded
The data on this page reflects Immuneering Corporation's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Aug 3, 2021
Last Round
Private Placement
Sep 26, 2025
Total Funding Raised
$433.4M
Company Overview
Immuneering (NAS: IMRX) is a biopharmaceutical company dedicated to enhancing patient outcomes in challenging oncologic and neurologic diseases through its advanced computational Disease Cancelling Technology platform and expertise in translational bioinformatics.
Sector
Healthcare
AI Layer
Infrastructure
Keywords
Immuneering Corporation Comparables
Compare Immuneering Corporation with similar companies based on industry and business-model similarity.
No public comparables are available for Immuneering Corporation. Request access to learn about comparables coverage.
Request accessImmuneering Corporation Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Sep 26, 2025 | ||||
| Follow-on Offering | Sep 26, 2025 | ||||
| Private Placement | Aug 26, 2025 | ||||
| IPO | Aug 3, 2021 | ||||
| Series B | Jan 5, 2021 | ||||
Series A | Oct 4, 2019 |
Immuneering Corporation Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| Perceptive Advisors | Series B |
| Guggenheim Securities | IPO |
| LYFE Capital | Series B |
| Morgan Stanley | IPO |
| T. Rowe Price | Series B |
| Citadel | Series B |
Immuneering Corporation Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access